Global Antimicrobial Susceptibility Testing Market Size & Share is Projected to Reach Worth USD 4.70 Billion by 2027 | BlueWeave

A study recently conducted by the strategic consulting and market research firm, BlueWeave Consulting, revealed that the global antimicrobial susceptibility testing market was worth USD 3.19 billion in 2020 and is further projected to reach USD 4.70 billion by 2027. The emergence of multidrug-resistant microbial strains like MRSA, Klebsiella pneumonia, Acinetobacter baumanii, etc., is the primary cause of the growth of the global antimicrobial susceptibility market. Apart from that, the growing cases of infectious diseases across the globe, coupled with increasing government funding and initiatives, and automated rapid AST (Antimicrobial susceptibility testing) methods are some of the key factors aiding the rapid growth of the global antimicrobial susceptibility testing market.

Browse report URL for more information about global antimicrobial susceptibility testing market @ https://www.blueweaveconsulting.com/report/antimicrobial-susceptibility-testing-market-report

Growing cases of infectious diseases acting as a catalyst for the global antimicrobial susceptibility testing market

According to Columbia University's Stephen Morse, emerging infections are infections that are rapidly expanding in frequency or geographic range, such as HIV/AIDS, severe acute respiratory syndrome (SARS), Ebola hemorrhagic fever, and Nipah virus encephalitis. The emergence of new infections and microbial strains into a host population and its establishment within the said population is mainly due to the vast and highly uncharacterized “zoonotic pool” of possible human pathogens as well as the increasing opportunities for infection caused by ecological upheaval and globalization.

Human activity, however, is making the transition very easy by creating efficient pathways for pathogen transmission around the globe. For example, the anti-vaxxers movement in the U.S. for flu vaccination led to a decrease in the vaccination rate. As a result, the vaccination rate in 2018 was 37.1% which was 6.2% lower than the vaccination rate in 2017. Due to such emergence of infectious diseases caused by human activities, AST has become imperative, thus aiding in the growth of the global antimicrobial susceptibility testing market.

Increasing prevalence of multidrug-resistant microbial strains making antimicrobial susceptibility testing an imperative process

Antimicrobial Agents (AMA) are the secondary metabolites produced by microorganisms that selectively suppress the growth or kill other microorganisms at a very low concentration with minimum injury to the host cell. Antibiotic-resistant bacteria are an essentially inevitable outcome of the extensive use of antimicrobial agents. The discovery, commercialization, and widespread administration of antimicrobial substances ushered in a new era in contemporary medicine, altering the therapeutic paradigm for treating infections. Unfortunately, the successful outcomes of critically sick patients have been jeopardized due to a considerable increase in antibiotic resistance among prevalent bacterial infections. As a result, antibiotic resistance is one of the three most serious public health problems of the 21st century, according to the World Health Organization.

The emergence of multidrug-resistant organisms in the hospital environment and community settings suggests that reservoirs of antibiotic-resistant bacteria are present even outside the hospital. The answer is "survival of the fittest," which explains the enormous genetic flexibility of bacterial pathogens that stimulate specialized reactions, culminating in mutational adaptations. Resistance to practically all antibiotics currently available in clinical practice results from the acquisition of genetic material or the modification of gene expression. Therefore, to prevent paradoxical worsening of the patient's condition due to over-medication or under-medication, antimicrobial susceptibility testing has become imperative to treat microbial infection, leading to the growth of the global antimicrobial susceptibility testing market.

Browse TOC with Facts and Figures @ https://www.blueweaveconsulting.com/report/antimicrobial-susceptibility-testing-market-report/toc

Global antimicrobial susceptibility testing market by end-user

Based on the end-user, the global antimicrobial susceptibility testing market is segmented into hospitals and diagnostic centers, pharmaceutical and biotechnology companies, research & academic institutes, clinical research organizations (CROS). The hospitals segment hold the largest share in the global antibiotic susceptibility testing market as they are prominent end-users of antimicrobial susceptibility testing products. The large share of hospitals is also due to the growing prevalence of hospital-acquired infections, such as Hospital-Acquired Pneumonia and Ventilator Acquired Pneumonia. Furthermore, due to the presence of high-tech and well-equipped facilities and equipment, as well as highly trained/skilled technicians in diagnostic laboratories, as well as various endeavors by important players to provide efficient AST products to diagnostic laboratories, the diagnostic center segment is likely to witness exemplary growth during the forecast period.

Global antimicrobial susceptibility testing market by region

Based on region, the global antimicrobial susceptibility testing market is segmented into North America, Europe, the Asia-Pacific, the Middle East & Africa, and Latin America. Out of these regions, North America has the largest share of the global antimicrobial susceptibility testing market. North America’s dominance can be attributed to the growing investment in R&D to develop novel automated AST systems, technological advancements in antimicrobial susceptibility products, and increasing cases of infections like Lyme Disease and West Nile. On the other hand, the Asia Pacific antimicrobial susceptibility testing market is also growing owing to the increasing public health awareness, increasing population, and over-consumption of antibiotics.

Impact of COVID-19

With the outbreak of the COVID-19, major industries and businesses, as well as people's daily lives, have been disrupted. To curb the spread of the COVID-19 virus, almost every country had to impose nationwide lockdown and. Since the pandemic, hospitals have prioritized COVID-19 treatment; consequently, the usage of automated antimicrobial susceptibility testing technologies such as the Accelerate Pheno system, MicroScan WalkAway system, and Sensitive ARIS system has been drastically reduced. Additionally, the stringent government rules and regulations during the pandemic on new product launches and instrument approval also severely impacted the global antimicrobial susceptibility testing market.

Request For Free Sample Report @ https://www.blueweaveconsulting.com/report/antimicrobial-susceptibility-testing-market-report/report-sample

Competitive Landscape

The global antimicrobial susceptibility testing market is thriving owing to the growing prevalence of infectious diseases, emergence of antimicrobial-resistant strains, and government initiatives. As a result, the market is attracting many key players. Some of the key players in the global antimicrobial susceptibility testing market are PML Microbiologicals Inc., BioMérieux SA, QuantaMatrix Inc., MP Biomedicals, InvivoGen, Biotron Ltd, Becton, Dickinson and Company, Thermo Fisher Scientific, Danaher Corporation, Roche Diagnostics Limited, Bio-Rad Laboratories, Inc., Merck KGaA, Accelerate Diagnostics, Inc., Liofilchem S.r.l., ZHUHAI DL BIOTECH Co., Ltd., ELITechGroup, Halifax S.r.l., Hi-Media Laboratories, Genefluidics, Inc., Creative Diagnostics, and other prominent players.

Don’t miss the business opportunity of the global antimicrobial susceptibility testing market. Consult our analysts to gain crucial insights and facilitate your business growth.

The report's in-depth analysis provides information about growth potential, upcoming trends, and statistics of the global antimicrobial susceptibility testing market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the ­­­global antimicrobial susceptibility testing market, along with industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Please find below some related reports:

https://www.blueweaveconsulting.com/report/middle-east-and-africa-critical-care-equipment-market-bwc20009

https://www.blueweaveconsulting.com/report/french-medical-equipment-market-bwc20008

Contact Us:

BlueWeave Consulting & Research Pvt. Ltd
US: +1 866 658 6826 | +1 425 320 4776
UK: +44 1865 60 0662
Email – info@blueweaveconsulting.com
LinkedIn Page: https://www.linkedin.com/company/blueweaveconsulting/

112 - H160 - BSI Business Park Sector - 63, Noida U.P. - India

About Us



Blue Weave Consulting provides all-inclusive Market Intelligence (MI) Solutions to businesses regarding various products and services online & offline. We offer comprehensive market research reports by analyzing both qualitative and quantitative data to boost your business solution's performance. BWC has built its reputation from the scratches by delivering quality inputs and nourishing long-lasting relationships with its clients. We are a promising digital MI solutions company providing agile assistance to make your business endeavors successful.

This release was published on openPR.